Loading...
OTCM
OCMLF
Market cap20mUSD
, Last price  
USD
Name

Oncosil Medical Ltd

Chart & performance

D1W1MN
OTCM:OCMLF chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-53.83%
Rev. 5Y
51.22%
Div Yld LY
—
Div Yld TTM
—
Revenues
2m
+43.92%
1,758,0002,064,0002,303,0002,087,124000315,8572,757,0003,837,0003,514,0004,448,0003,626,0002,764,000213,070231,789367,677516,6321,170,7931,684,978
Net income
-11m
L-28.08%
-1,674,000-2,767,000-440,000-1,712,021-1,458,000-431,000-879,000-6,865,000-2,879,000-4,769,000-7,016,000-8,540,000-8,567,000-4,262,000-10,434,000-10,727,000-11,343,000-11,914,000-15,099,844-10,860,122
CFO
-10m
L-13.18%
-1,345,466-2,180,247-103,974154,348-316,665-305,783-471,908-6,369,942-171,159-4,572,568-6,109,845-8,397,341-7,501,154-4,456,079-8,815,401-10,110,178-11,315,634-10,824,337-12,062,301-10,472,438

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Key people

Shelley Steyn
Chief Financial Officer · since 2025
Nigel Lange
Chief Executive Officer, Managing Director, Executive Director · since 2021
Tim Luscombe
Joint Company Secretary · since 2025
David Wood
Joint Company Secretary · since 2025
Thomas Duthy
Non-Executive Director · since 2025
Peter Hall
Non-Executive Director · since 2024
Gabriel Liberatore
Non-Executive Director · since 2023
Lelde Smits
Non-Executive Director · since 2025
URL
https://www.oncosil.com/
IPO date
Aug 15, 2005
Employees
2
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT